About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Giant Cell Arteritis - Optimization of Diagnostics | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT05248906

Giant Cell Arteritis - Optimization of Diagnostics

Giant cell arteritis - Optimization of diagnostics

Lead sponsor: Rigshospitalet, Denmark•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Rigshospitalet, Denmark

A prospective study. Investigating the use of ultrasound, temporal artery biopsy, biomarkers and 18F-fluorodeoxyglucose positron emission tomography-computed tomography for establishing a diagnosis of giant cell (temporal) arteritis.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Clinical suspicion of giant cell arteritis
•Meets the American College of Rheumatology Criteria:
•Age at disease onset =\> 50 years New headache Temporal artery abnormality Elevated erythrocyte sedimentation rate \>=50 mm/hour Abnomal artery biopsy

Exclusion Criteria

•Active cancer Use of steroid for more than a week (the prior 6 months)

Related studies

The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.

NCT07246577 · Giant Cell Arteritis (GCA)

Rheumatology Patient Registry and Biorepository

NCT04402086 · Rheumatic Diseases, Adult Onset Still Disease, and more

RECRUITINGPhase 3

Abatacept for the Treatment of Giant Cell Arteritis

NCT04474847 · Giant Cell Arteritis

RECRUITINGPhase 2

Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

NCT06887062 · Large Vessel Vasculitis, Giant Cell Arteritis (GCA), and more

Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)

NCT05865054 · Giant Cell Arteritis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 2, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment110

Start dateMar 2021

Last updatedApr 2, 2025

Condition

Giant Cell Arteritis

Locations shown

Rigshospitalet

Copenhagen

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions